CytomX Therapeutics (CTMX) Competitors $2.40 +0.03 (+1.27%) Closing price 04:00 PM EasternExtended Trading$2.40 +0.00 (+0.21%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX vs. XERS, PHAR, REPL, VIR, GYRE, PHAT, NUVB, DNA, DAWN, and IMTXShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Xeris Biopharma (XERS), Pharming Group (PHAR), Replimune Group (REPL), Vir Biotechnology (VIR), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), Nuvation Bio (NUVB), Ginkgo Bioworks (DNA), Day One Biopharmaceuticals (DAWN), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. CytomX Therapeutics vs. Its Competitors Xeris Biopharma Pharming Group Replimune Group Vir Biotechnology Gyre Therapeutics Phathom Pharmaceuticals Nuvation Bio Ginkgo Bioworks Day One Biopharmaceuticals Immatics Xeris Biopharma (NASDAQ:XERS) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability. Which has better earnings & valuation, XERS or CTMX? CytomX Therapeutics has lower revenue, but higher earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXeris Biopharma$203.07M3.67-$54.84M-$0.30-15.90CytomX Therapeutics$138.10M1.40$31.87M$0.485.00 Do analysts prefer XERS or CTMX? Xeris Biopharma currently has a consensus price target of $6.25, suggesting a potential upside of 31.03%. CytomX Therapeutics has a consensus price target of $5.33, suggesting a potential upside of 122.22%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than Xeris Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in XERS or CTMX? 42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, XERS or CTMX? Xeris Biopharma has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Does the media favor XERS or CTMX? In the previous week, CytomX Therapeutics had 2 more articles in the media than Xeris Biopharma. MarketBeat recorded 2 mentions for CytomX Therapeutics and 0 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.00 equaled CytomX Therapeutics'average media sentiment score. Company Overall Sentiment Xeris Biopharma Neutral CytomX Therapeutics Neutral Is XERS or CTMX more profitable? CytomX Therapeutics has a net margin of 28.22% compared to Xeris Biopharma's net margin of -20.25%. Xeris Biopharma's return on equity of 0.00% beat CytomX Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xeris Biopharma-20.25% N/A -12.07% CytomX Therapeutics 28.22%-553.71%32.21% SummaryCytomX Therapeutics beats Xeris Biopharma on 11 of the 15 factors compared between the two stocks. Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$193.49M$2.88B$5.46B$8.92BDividend YieldN/A2.44%5.24%4.04%P/E Ratio5.0020.8027.0120.12Price / Sales1.40193.35380.1493.35Price / Cash6.9141.7026.2128.59Price / Book-240.007.487.995.57Net Income$31.87M-$55.04M$3.16B$248.40M7 Day Performance1.69%5.44%3.69%6.04%1 Month Performance-9.09%2.38%2.91%7.69%1 Year Performance84.62%5.53%34.30%20.97% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics3.9239 of 5 stars$2.40+1.3%$5.33+122.2%+83.7%$193.49M$138.10M5.00170XERSXeris Biopharma3.6131 of 5 stars$4.67-0.6%$6.25+33.8%+122.7%$730.30M$203.07M-15.57290Positive NewsPHARPharming Group2.7844 of 5 stars$10.68-2.9%$30.00+181.0%+28.8%$726.29M$297.20M-53.38280Gap UpHigh Trading VolumeREPLReplimune Group4.1728 of 5 stars$9.29-0.4%$20.83+124.3%+19.0%$719.22MN/A-3.03210VIRVir Biotechnology3.19 of 5 stars$5.04-2.5%$32.86+551.9%-38.2%$696.73M$74.21M-1.19580News CoverageGYREGyre Therapeutics0.0875 of 5 stars$7.35-0.9%N/A-38.7%$689.14M$105.76M367.6840PHATPhathom Pharmaceuticals3.4531 of 5 stars$9.59-1.5%$17.50+82.5%-15.9%$669.48M$55.25M-1.83110NUVBNuvation Bio3.4285 of 5 stars$1.96+1.3%$7.17+266.6%-31.4%$665.21M$7.87M-0.8360Gap UpHigh Trading VolumeDNAGinkgo Bioworks1.1328 of 5 stars$11.29+19.3%$5.77-48.9%N/A$660.80M$227.04M-1.23640Positive NewsDAWNDay One Biopharmaceuticals1.7232 of 5 stars$6.50+0.5%$30.57+370.3%-51.6%$658.84M$131.16M-9.1560IMTXImmatics2.4317 of 5 stars$5.38-0.9%$14.67+172.6%-52.9%$653.94M$168.65M-31.65260Positive News Related Companies and Tools Related Companies Xeris Biopharma Competitors Pharming Group Competitors Replimune Group Competitors Vir Biotechnology Competitors Gyre Therapeutics Competitors Phathom Pharmaceuticals Competitors Nuvation Bio Competitors Ginkgo Bioworks Competitors Day One Biopharmaceuticals Competitors Immatics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTMX) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
